GB2235860A - Antioxidant containing blood substitutes - Google Patents
Antioxidant containing blood substitutes Download PDFInfo
- Publication number
- GB2235860A GB2235860A GB8914589A GB8914589A GB2235860A GB 2235860 A GB2235860 A GB 2235860A GB 8914589 A GB8914589 A GB 8914589A GB 8914589 A GB8914589 A GB 8914589A GB 2235860 A GB2235860 A GB 2235860A
- Authority
- GB
- United Kingdom
- Prior art keywords
- blood substitutes
- hemoglobin
- limited
- antioxidant
- iron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Blood substitutes containing iron e.g. hemoglobin are formulated so that they are less toxic by the addition of the antioxidant, (+)-Cyanidanol-3, or a strong antioxidant such as Butylated hydroxytoluene or Butylated hydroxyanisole.
Description
Blood Substitutes-Antioxidant Formulas In the use of blood substitutes which are derived from hemoglobin or other iron-containing substances, it has been found that many of the tissues of the body are adversely affected. This effect is found in total or partial transfusions or in the use of blood substitutes during angioplasty or perfusion of transplant tissue.
The addition of a strong antiotidant can prevent this problem.
One novelty, therefore, of this invention is the use of the antioxidant (+)-cyanidanol-3 in the preparation or administration of blood substitutes which pre derived from hemoglobin or other iron containing molecules.
Other strong antioxidants which may be utilized include butylated hydroxytoluene, and butylated hydroxyanisole.
Other similar strong antioxidants may be suitable.
Example 1
The hemoglobin solution is prepared from outdated erythrocyte concentrates by a method of several steps as described by
Bonhard K. and Kothe N. The erythrocyte concentrates are pooled, repeatedly washed with 10 percent glucose solution, chemically sterilized with B-propiolacta , hemolyzed by the addition of distilled water; stroma removal by precipitation, centrifugation, and filtration, concentration of the hemoglobin to 22 percent weight by volume; its conversion to desoxyhemoglobin; reaction with pridoxal-- phosphate; cross-linking with glutardialdellyde and reduction with sodium borohydridc.
Each unit is then reconstituted with 500 ml. of phosphate buffer solution of pH 7.3 containing 100 mg. of (+)-Cyanidanol 3.
Although the example here given utilizes adult human hemoglobin which is then destromatized, cross-linked and mo91fied with a 2,3 diphosphoglycerate substitute, it is ciear that any iron containing blood substitute may be utilized without deviating from the novelty of the principle described herein.
Although the example here given utilizes (+)-Cyanidanol-3 as the strong antioxidant, it is clear that butylated hydroxytoluene, butylated hydroxyanisole, or any other suitably strong and relatively nontoxic antioxidant may be utilized without deviating from the novelty of the principle described herein.
Example 2
The hemoglobin solution is prepared from outdated erythrocyte concentrates by a method of several steps as described by
Bonhard K. and Kothe N. The erythrocyte concentrates are pooled, repeatedly washed with 10 percent glucose solution, chemically sterilized with B-propiolactone, hemolyzed by the addition of distilled watery stroma removal by precipitation, centrifugation, and filtration, concentration of the hemoglobin to 22 percent weight by volume; its conversion to desoxyhemoglobin; reaction with bis 3,5 dibromosalicylfumarate; not crosslinked and reduced with sodium borohydride.
Each unit is then reconstituted with 500 ml of phosphate buffer solution of pH 7.3 containing 10 mg of Butylated
Hydroxyanisole and/or 10 mg of Butylated hydroxytoluene dispersed with 1 mg of Tween 80.
Claims (3)
- The invention is not limited to the precise construction herein disclosed but, rather, includes all modification and improvements, encompassed within the scope of the following claims.I claim: 1. The use of the antioxidant (+)-Cyanidanol-3 in the formulation of blood substitutes which contain iron or are derived from iron-containing substances, such as, but not limited to hemoglobin.
- 2. The use of other strong antioxidants, including but not limited to butylated hydroxytoluene and/or butylated hydroxyanisole, in formulating blood substitutes which contain iron, including, but not limited to those derived from hemoglobin.
- 3. The concomitant administration of antioxidants, includ ng, but not limited to (+)-Cyanidanol-3, butylated hydroxytoluene, and/or butylated hydroxyanisole during the use or administration of blood substitutes containing iron, such as those derived from hemoglobin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8914589A GB2235860A (en) | 1989-06-26 | 1989-06-26 | Antioxidant containing blood substitutes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8914589A GB2235860A (en) | 1989-06-26 | 1989-06-26 | Antioxidant containing blood substitutes |
Publications (2)
Publication Number | Publication Date |
---|---|
GB8914589D0 GB8914589D0 (en) | 1989-08-16 |
GB2235860A true GB2235860A (en) | 1991-03-20 |
Family
ID=10659045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8914589A Withdrawn GB2235860A (en) | 1989-06-26 | 1989-06-26 | Antioxidant containing blood substitutes |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2235860A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1786018B (en) * | 2005-12-12 | 2011-06-22 | 天津协和生物科技发展有限公司 | Separation and purification of high purity hemoglobin and virus inactivation technology |
-
1989
- 1989-06-26 GB GB8914589A patent/GB2235860A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1786018B (en) * | 2005-12-12 | 2011-06-22 | 天津协和生物科技发展有限公司 | Separation and purification of high purity hemoglobin and virus inactivation technology |
Also Published As
Publication number | Publication date |
---|---|
GB8914589D0 (en) | 1989-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rane et al. | Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants | |
CA2125401A1 (en) | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of making and using them | |
JP2001523225A (en) | Improved storage and preservation of blood products | |
HU227992B1 (en) | Interferon conjugates, process for prepairing them, pharmaceutical compositions, containing them and use of them | |
US4609372A (en) | Heat sterilizable storage solution for red blood cells | |
US3864478A (en) | Storage-stable hemoglobin solutions and method for their preparation | |
JP2008543987A (en) | Method for producing low molecular weight heparin | |
AU696954B2 (en) | Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications | |
Knight et al. | Degradation by cultured fibroblasts and macrophages of unmodified and 1, 2-cyclohexanedione-modified low-density lipoprotein from normal and homozygous familial hypercholesterolaemic subjects | |
Gribble | Fluoroacetate toxicity | |
Ogata et al. | Mercury uptake by acatalasemia mice and their erythrocytes, lung and liver homogenates | |
JPS592686A (en) | Powder pharmaceutical preparation of myeloperoxidase | |
CA2106558A1 (en) | Blood preserving composition and method for preserving blood | |
FR2488695A1 (en) | PROCESS AND KIT FOR MARKING RED GLOBLES WITH TECHNETIUM-99M | |
DE69026513T2 (en) | POLYHEMOGLOBIN STABILIZED BY PURINE DERIVATIVES AND GLUTATHION | |
Chaplin et al. | The effects of a phenothiazine derivative (RP. 3300) on red cell preservation | |
BERENS et al. | Pentoxifylline in the isolated perfused rat kidney | |
GB2235860A (en) | Antioxidant containing blood substitutes | |
CA2067371A1 (en) | Stable hemoglobin based composition and method to store same | |
US5362492A (en) | Method of inhibiting multiple organ failure in trauma patients by administration of superoxide dismutase | |
Adam et al. | Penetration of ceftazidime into human tissue in patients undergoing cardiac surgery | |
EP0532706B1 (en) | REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS | |
JPH1160499A (en) | Antitumor agent | |
Vogelfanger et al. | NATURALLY OCCURRING IMMUNOSUPPRESSIVE AGENTS: I. THE PRESENCE IN NORMAL PIG LIVER OF A FACTOR POSSESSING IMMUNOSUPPRESSIVE PROPERTIES WITH RESPECT TO PIG LYMPHOID CELLS IN VITRO | |
EP0586381B1 (en) | Improved blood substitute |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |